Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Pathophysiological mechanisms leading to muscle loss in chronic kidney disease

Wang, Xiaonan H., Mitch, William E., Price, S. Russ · 2022 · Nature Reviews Nephrology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41581-021-00498-0

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 164

  1. Griffiths, R. D. Muscle mass, survival, and the elderly ICU patient. Nutrition 12, 456–458 (1996). · DOI
  2. Mitch, W. E. & Goldberg, A. L. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335, 1897–1905 (1996). · DOI · Paper page
  3. Hanna, R. M., Ghobry, L., Wassef, O., Rhee, C. M. & Kalantar-Zadeh, K. A practical approach to nutrition, protein-energy wasting, sarcopenia, and cachexia in patients with chronic kidney disease. Blood Purif. 49, 202–211 (2020). · DOI · Paper page
  4. Moorthi, R. N. & Avin, K. G. Clinical relevance of sarcopenia in chronic kidney disease. Curr. Opin. Nephrol. Hyperten. 26, 219–228 (2017). · DOI · Paper page
  5. Sabatino, A., Cuppari, L., Stenvinkel, P., Lindholm, B. & Avesani, C. M. Sarcopenia in chronic kidney disease: what have we learned so far? J. Nephrol. 34, 1347–1372 (2020). · DOI · Paper page
  6. Lowrie, E. G. & Lew, N. L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 15, 458–482 (1990). · DOI · Paper page
  7. Carrero, J. J. et al. Global prevalence of protein-energy wasting in kidney disease: a meta-analysis of contemporary observational studies from the International Society of Renal Nutrition and Metabolism. J. Ren. Nutr. 28, 380–392 (2018). · DOI · Paper page
  8. Kim, J. C., Kalantar-Zadeh, K. & Kopple, J. D. Frailty and protein-energy wasting in elderly patients with end stage kidney disease. J. Am. Soc. Nephrol. 24, 337–351 (2013). · DOI · Paper page
  9. Zelle, D. M. et al. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin. J. Am. Soc. Nephrol. 6, 898–905 (2011). · DOI · Paper page
  10. Tentori, F. et al. Physical exercise among participants in the Dialysis Outcomes and Practice Patterns Study (DOPPS): correlates and associated outcomes. Nephrol. Dial. Transpl. 25, 3050–3062 (2010). · DOI · Paper page
  11. Kovesdy, C. P. & Kalantar-Zadeh, K. Why is protein-energy wasting associated with mortality in chronic kidney disease? Sem. Nephrol. 29, 3–14 (2009). · DOI · Paper page
  12. Bailey, J. L. et al. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J. Clin. Invest. 97, 1447–1453 (1996). · DOI · Paper page
  13. Stenvinkel, P., Carrero, J. J., von Walden, F., Ikizler, T. A. & Nader, G. A. Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies. Nephrol. Dial. Transpl. 31, 1070–1077 (2016). · DOI · Paper page
  14. Kim, I. Y., Suh, S. H., Lee, I. K. & Wolfe, R. R. Applications of stable, nonradioactive isotope tracers in in vivo human metabolic research. Exp. Mol. Med. 48, e203 (2016). · DOI · Paper page
  15. Clark, A. S. & Mitch, W. E. Comparison of protein synthesis and degradation in incubated and perfused muscle. Biochem. J. 212, 649–653 (1983). · DOI
  16. Wang, X. H., Du, J., Klein, J. D., Bailey, J. L. & Mitch, W. E. Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function. Kidney Int. 76, 751–759 (2009). · DOI
  17. Chen, C. F., You, Z. H., Yang, W. C. & Lin, C. C. Hypokalaemic paralysis with seemingly pH-neutralized blood gas: liquorice-induced mineralocorticoid effect superimposed on renal tubular acidosis. Acta Clin. Belg. 66, 403 (2011).
  18. Deger, S. M. et al. Systemic inflammation is associated with exaggerated skeletal muscle protein catabolism in maintenance hemodialysis patients. JCI Insight 2, e95185 (2017). · DOI
  19. Garibotto, G. et al. Insulin sensitivity of muscle protein metabolism is altered in patients with chronic kidney disease and metabolic acidosis. Kidney Int. 88, 1419–1426 (2015). · DOI
  20. Adey, D., Kumar, R., McCarthy, J. T. & Nair, K. S. Reduced synthesis of muscle proteins in chronic renal failure. Am. J. Physiol. Endocrinol. Metab. 278, E219–E225 (2000). · DOI · Paper page
  21. Raj, D. S. et al. Coordinated increase in albumin, fibrinogen, and muscle protein synthesis during hemodialysis: role of cytokines. Am. J. Physiol. Endocrinol. Metab. 286, E658–E664 (2004). · DOI
  22. van Vliet, S. et al. Dysregulated handling of dietary protein and muscle protein synthesis after mixed-meal ingestion in maintenance hemodialysis patients. Kidney Int. Rep. 3, 1403–1415 (2018). · DOI
  23. May, R. C., Kelly, R. A. & Mitch, W. E. Mechanisms for defects in muscle protein metabolism in rats with chronic uremia. Influence of metabolic acidosis. J. Clin. Invest. 79, 1099–1103 (1987). · DOI · Paper page
  24. Du, J., Mitch, W. E., Wang, X. & Price, S. R. Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-κB. J. Biol. Chem. 275, 19661–19666 (2000). · DOI
  25. Meyer-Schwesinger, C. The ubiquitin-proteasome system in kidney physiology and disease. Nat. Rev. Nephrol. 15, 393–411 (2019). · DOI · Paper page
  26. Lokireddy, S. et al. Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting. Am. J. Physiol. Cell Physiol. 303, C512–C529 (2012). · DOI
  27. Cohen, S. et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 185, 1083–1095 (2009). · DOI · Paper page
  28. Li, H. H. et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J. Clin. Invest. 114, 1058–1071 (2004). · DOI · Paper page
  29. Rom, O., Kaisari, S., Reznick, A. Z. & Aizenbud, D. in Oxidative Stress and Cardiorespiratory Function (ed. Pokorski M.) 1–8 (Springer, 2014). · DOI
  30. Schwerk, C. & Schulze-Osthoff, K. Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem. Pharmacol. 66, 1453–1458 (2003). · DOI · Paper page
  31. Du, J. et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J. Clin. Invest. 113, 115–123 (2004). · DOI · Paper page
  32. Wang, X. H. et al. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J. Biol. Chem. 285, 21249–21257 (2010). · DOI · Paper page
  33. Workeneh, B. T. et al. Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. J. Am. Soc. Nephrol. 17, 3233–3239 (2006). · DOI
  34. Hu, J. et al. XIAP reduces muscle proteolysis induced by CKD. J. Am. Soc. Nephrol. 21, 1174–1183 (2010). · DOI
  35. Su, Z. et al. Chronic kidney disease induces autophagy leading to dysfunction of mitochondria in skeletal muscle. Am. J. Physiol. Ren. Physiol. 312, F1128–F1140 (2017). · DOI
  36. Morel, E. et al. Autophagy: a druggable process. Ann. Rev. Pharmacol. Toxicol. 57, 375–398 (2017). · DOI · Paper page
  37. Hariharan, N. et al. Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ. Res. 107, 1470–1482 (2010). · DOI · Paper page
  38. Jang, M. et al. AMPK contributes to autophagosome maturation and lysosomal fusion. Sci. Rep. 8, 12637 (2018). · DOI
  39. Corona Velazquez, A. F. & Jackson, W. T. So many roads: the multifaceted regulation of autophagy induction. Mol. Cell Biol. 38, e00303–e00318 (2018). · DOI
  40. Zhang, Y. Y. et al. CKD autophagy activation and skeletal muscle atrophy–a preliminary study of mitophagy and inflammation. Eur. J. Clin. Nutr. 73, 950–960 (2019). · DOI
  41. Gunta, S. S. & Mak, R. H. Ghrelin and leptin pathophysiology in chronic kidney disease. Pediatr. Nephrol. 28, 611–616 (2013). · DOI
  42. Bailey, J. L., Zheng, B., Hu, Z., Price, S. R. & Mitch, W. E. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J. Am. Soc. Nephrol. 17, 1388–1394 (2006). · DOI · Paper page
  43. Hodson, N., West, D. W. D., Philp, A., Burd, N. A. & Moore, D. R. Molecular regulation of human skeletal muscle protein synthesis in response to exercise and nutrients: a compass for overcoming age-related anabolic resistance. Am. Physiol. Cell Physiol. 317, C1061–C1078 (2019). · DOI
  44. Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A. & Goldberg, A. L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl Acad. Sci. USA 98, 14440–14445 (2001). · DOI · Paper page
  45. von Walden, F. Ribosome biogenesis in skeletal muscle: coordination of transcription and translation. J. Appl. Physiol. 127, 591–598 (2019). · DOI
  46. Gao, Y., Ordas, R., Klein, J. D. & Price, S. R. Regulation of caspase-3 activity by insulin in skeletal muscle cells involves both PI3-kinase and MEK-1/2. J. Appl. Physiol. 105, 1772–1778 (2008). · DOI
  47. Carrero, J. J. et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J. Ren. Nutr. 23, 77–90 (2013). · DOI · Paper page
  48. de Brito-Ashurst, I., Varagunam, M., Raftery, M. J. & Yaqoob, M. M. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J. Am. Soc. Nephrol. 20, 2075–2084 (2009). · DOI · Paper page
  49. Hu, Z., Wang, H., Lee, I. H., Du, J. & Mitch, W. E. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J. Clin. Invest. 119, 3059–3069 (2009).
  50. Graham, K. A., Reaich, D., Channon, S. M., Downie, S. & Goodship, T. H. Correction of acidosis in hemodialysis decreases whole-body protein degradation. J. Am. Soc. Nephrol. 8, 632–637 (1997). · DOI · Paper page
  51. Reaich, D. et al. Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am. J. Physiol. 265, E230–E235 (1993).
  52. Kraut, J. A. & Madias, N. E. Adverse deffects of the metabolic acidosis of chronic kidney disease. Adv. Chronic Kidney Dis. 24, 289–297 (2017). · DOI
  53. Franch, H. A. et al. Acidosis impairs insulin receptor substrate-1-associated phosphoinositide 3-kinase signaling in muscle cells: consequences on proteolysis. Am. J. Physiol. Ren. Physiol. 287, F700–F706 (2004). · DOI
  54. Mitch, W. E. et al. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J. Clin. Invest. 93, 2127–2133 (1994). · DOI · Paper page
  55. Isozaki, U., Mitch, W. E., England, B. K. & Price, S. R. Protein degradation and increased mRNAs encoding proteins of the ubiquitin-proteasome proteolytic pathway in BC3H1 myocytes require an interaction between glucocorticoids and acidification. Proc. Natl Acad. Sci. USA 93, 1967–1971 (1996). · DOI
  56. May, R. C., Kelly, R. A. & Mitch, W. E. Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. J. Clin. Invest. 77, 614–621 (1986). · DOI · Paper page
  57. Price, S. R., England, B. K., Bailey, J. L., Van Vreede, K. & Mitch, W. E. Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle. Am. J. Physiol. Cell Physiol. 267, C955–C960 (1994). · DOI · Paper page
  58. Garibotto, G. et al. Skeletal muscle protein synthesis and degradation in patients with chronic renal failure. Kidney Int. 45, 1432–1439 (1994). · DOI
  59. Wing, S. S. & Goldberg, A. L. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am. J. Physiol. Endocrinol. Metab. 264, E668–E676 (1993). · DOI · Paper page
  60. Mihai, S. et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J. Immunol. Res. 2018, 2180373 (2018). · DOI · Paper page
  61. Collins, R. A. & Grounds, M. D. The role of tumor necrosis factor-alpha (TNF-α) in skeletal muscle regeneration. Studies in TNF-α(-/-) and TNF-α(-/-)/LT-α(-/-) mice. J. Histochem. Cytochem. 49, 989–1001 (2001). · DOI · Paper page
  62. Hu, L. et al. Low-frequency electrical stimulation attenuates muscle atrophy in CKD–a potential treatment strategy. J. Am. Soc. Nephrol. 26, 626–635 (2015). · DOI
  63. Raj, D. S. et al. Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis. Kidney Int. 73, 1054–1061 (2008). · DOI
  64. Thoma, A. & Lightfoot, A. P. in Muscle Atrophy (ed. Xiao J.) 267–279 (Springer, 2018). · DOI · Paper page
  65. Zhang, L. et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J. Am. Soc. Nephrol. 20, 604–612 (2009). · DOI · Paper page
  66. Carson, J. A. & Baltgalvis, K. A. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport. Sci. Rev. 38, 168–176 (2010). · DOI · Paper page
  67. Ikizler, T. A. et al. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int. 84, 1096–1107 (2013). · DOI · Paper page
  68. Walker, R. G. et al. Biochemistry and biology of GDF11 and myostatin: similarities, differences, and questions for future investigation. Circ. Res. 118, 1125–1141 (2016). · DOI · Paper page
  69. Verzola, D., Barisione, C., Picciotto, D., Garibotto, G. & Koppe, L. Emerging role of myostatin and its inhibition in the setting of chronic kidney disease. Kidney Int. 95, 506–517 (2019). · DOI
  70. Kaji, H. Effects of myokines on bone. Bonekey Rep. 5, 826 (2016). · DOI
  71. Breitbart, A., Auger-Messier, M., Molkentin, J. D. & Heineke, J. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am. J. Physiol. Heart Circ. Physiol. 300, H1973–H1982 (2011). · DOI
  72. Goodman, C. A., McNally, R. M., Hoffmann, F. M. & Hornberger, T. A. Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo. Mol. Endocrinol. 27, 1946–1957 (2013). · DOI
  73. Zhang, L. et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. 25, 1653–1663 (2011). · DOI · Paper page
  74. Verzola, D. et al. Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease. Kidney Int. 79, 773–782 (2011). · DOI
  75. Yano, S. et al. Relationship between blood myostatin levels and kidney function: Shimane CoHRE Study. PLoS ONE 10, e0141035 (2015). · DOI
  76. Mitch, W. E. Proteolytic mechanisms, not malnutrition, cause loss of muscle mass in kidney failure. J. Ren. Nutr. 16, 208–211 (2006). · DOI
  77. Mitch, W. E. Cachexia in chronic kidney disease: a link to defective central nervous system control of appetite. J. Clin. Invest. 115, 1476–1478 (2005). · DOI
  78. Butler, A. A. et al. Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. Nat. Neurosci. 4, 605–611 (2001). · DOI · Paper page
  79. Heimburger, O., Lonnqvist, F., Danielsson, A., Nordenstrom, J. & Stenvinkel, P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J. Am. Soc. Nephrol. 8, 1423–1430 (1997). · DOI · Paper page
  80. Stenvinkel, P., Lindholm, B., Lonnqvist, F., Katzarski, K. & Heimburger, O. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J. Am. Soc. Nephrol. 11, 1303–1309 (2000). · DOI · Paper page
  81. Nishikawa, M. et al. Measurement of serum leptin in patients with chronic renal failure on hemodialysis. Clin. Nephrol. 51, 296–303 (1999).
  82. Arbeiter, A. K. et al. Ghrelin and other appetite-regulating hormones in paediatric patients with chronic renal failure during dialysis and following kidney transplantation. Nephrol. Dial. Transplant. 24, 643–646 (2009). · DOI
  83. Canpolat, N. et al. Leptin and ghrelin in chronic kidney disease: their associations with protein-energy wasting. Pediatr. Nephrol. 33, 2113–2122 (2018). · DOI
  84. Monzani, A. et al. Unacylated ghrelin and obestatin: promising biomarkers of protein energy wasting in children with chronic kidney disease. Pediatr. Nephrol. 33, 661–672 (2018). · DOI
  85. Buscher, A. K., Buscher, R., Hauffa, B. P. & Hoyer, P. F. Alterations in appetite-regulating hormones influence protein-energy wasting in pediatric patients with chronic kidney disease. Pediatr. Nephrol. 25, 2295–2301 (2010). · DOI
  86. Caliskan, Y. et al. Comparison of markers of appetite and inflammation between hemodialysis patients with and without failed renal transplants. J. Ren. Nutr. 22, 258–267 (2012). · DOI
  87. Chaves, F. M., Mansano, N. S., Frazao, R. & Donato, J. Jr Tumor necrosis factor α and interleukin-1β acutely inhibit AgRP neurons in the arcuate nucleus of the hypothalamus. Int. J. Mol. Sci. 21, 8928 (2020). · DOI
  88. Gordon, B. S., Kelleher, A. R. & Kimball, S. R. Regulation of muscle protein synthesis and the effects of catabolic states. Int. J. Biochem. Cell Biol. 45, 2147–2157 (2013). · DOI · Paper page
  89. Zhang, L. et al. Mechanisms regulating muscle protein synthesis in chronic kidney disease. J. Am. Soc. Nephrol. 31, 2573–2587 (2020). · DOI
  90. Wang, X. H. et al. Decreased miR-29 suppresses myogenesis in CKD. J. Am. Soc. Nephrol. 22, 2068–2076 (2011). · DOI
  91. Xu, J. et al. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int. 82, 401–411 (2012). · DOI · Paper page
  92. Wang, B. et al. MicroRNA-23a and microRNA-27a mimic exercise by ameliorating CKD-induced muscle atrophy. J. Am. Soc. Nephrol. 28, 2631–2640 (2017). · DOI
  93. Hudson, M. B. et al. miR-182 attenuates atrophy-related gene expression by targeting FoxO3 in skeletal muscle. Am. J. Physiol. Cell Physiol. 307, C314–C319 (2014). · DOI
  94. Gamboa, J. L. et al. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol. Rep. 4, e12780 (2016). · DOI · Paper page
  95. Roshanravan, B. et al. CKD and muscle mitochondrial energetics. Am. J. Kidney Dis. 68, 658–659 (2016). · DOI
  96. Yazdi, P. G., Moradi, H., Yang, J. Y., Wang, P. H. & Vaziri, N. D. Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease. Int. J. Clin. Exp. Med. 6, 532–539 (2013).
  97. Zhang, L., Wang, X. H., Wang, H., Du, J. & Mitch, W. E. Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J. Am. Soc. Nephrol. 21, 419–427 (2010). · DOI · Paper page
  98. Heron-Milhavet, L., Mamaeva, D., LeRoith, D., Lamb, N. J. & Fernandez, A. Impaired muscle regeneration and myoblast differentiation in mice with a muscle-specific KO of IGF-IR. J. Cell. Physiol. 225, 1–6 (2010). · DOI
  99. McFarlane, C. et al. Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp. Cell Res. 314, 317–329 (2008). · DOI · Paper page
  100. Levin, A. et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390, 1888–1917 (2017). · DOI · Paper page
  101. Bellizzi, V. et al. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int. 71, 245–251 (2007). · DOI
  102. Di Micco, L., Di Lullo, L., Bellasi, A. & Di Iorio, B. R. Very low protein diet for patients with chronic kidney disease: recent insights. J. Clin. Med. 8, 718 (2019). · DOI
  103. Milovanova, L. et al. Effect of essential amino acid small ketoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Klotho) in 3b-4 stages chronic small kidney disease patients: a randomized pilot study. Clin. Exp. Nephrol. 22, 1351–1359 (2018). · DOI
  104. Garneata, L., Stancu, A., Dragomir, D., Stefan, G. & Mircescu, G. Ketoanalogue-supplemented vegetarian very low-protein diet and CKD progression. J. Am. Soc. Nephrol. 27, 2164–2176 (2016). · DOI · Paper page
  105. Hara, H. et al. Protein energy wasting and sarcopenia in dialysis patients. Cont. Nephrol. 196, 243–249 (2018). · DOI
  106. Graham, K. A. et al. Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int. 49, 1396–1400 (1996). · DOI · Paper page
  107. Mak, R. H. Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int. 54, 603–607 (1998). · DOI
  108. Reaich, D. et al. Insulin-mediated changes in PD and glucose uptake after correction of acidosis in humans with CRF. Am. J. Physiol. Endocrinol. Metab. 268, E121–E126 (1995). · DOI
  109. Dobre, M., Rahman, M. & Hostetter, T. H. Current status of bicarbonate in CKD. J. Am. Soc. Nephrol. 26, 515–523 (2015). · DOI
  110. Loniewski, I. & Wesson, D. E. Bicarbonate therapy for prevention of chronic kidney disease progression. Kidney Int. 85, 529–535 (2014). · DOI
  111. Wilund, K. R., Viana, J. L. & Perez, L. M. A critical review of exercise training in hemodialysis patients: personalized activity prescriptions are needed. Exerc. Sport. Sci. Rev. 48, 28–39 (2013). · DOI
  112. Ikizler, T. A. et al. Metabolic effects of diet and exercise in patients with moderate to severe CKD: a randomized clinical trial. J. Am. Soc. Nephrol. 29, 250–259 (2018). · DOI
  113. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am. J. Kidney Dis. 45, S1–153 (2005).
  114. Gollie, J. M., Harris-Love, M. O., Patel, S. S. & Argani, S. Chronic kidney disease: considerations for monitoring skeletal muscle health and prescribing resistance exercise. Clin. Kidney J. 11, 822–831 (2018). · DOI
  115. Watson, E. L. et al. The effect of resistance exercise on inflammatory and myogenic markers in patients with chronic kidney disease. Front. Physiol. 8, 541 (2017). · DOI
  116. Dong, J. et al. The effect of resistance exercise to augment long-term benefits of intradialytic oral nutritional supplementation in chronic hemodialysis patients. J. Ren. Nutr. 21, 149–159 (2011). · DOI
  117. Cheema, B. et al. Randomized controlled trial of intradialytic resistance training to target muscle wasting in ESRD: the Progressive Exercise for Anabolism in Kidney Disease (PEAK) study. Am. J. Kidney Dis. 50, 574–584 (2007). · DOI
  118. Molsted, S., Harrison, A. P., Eidemak, I. & Andersen, J. L. The effects of high-load strength training with protein- or non-protein-containing nutritional supplementation in patients undergoing dialysis. J. Ren. Nutr. 23, 132–140 (2013). · DOI
  119. Su, Z. et al. Acupuncture plus low-frequency electrical stimulation (Acu-LFES) attenuates diabetic myopathy by enhancing muscle regeneration. PLoS ONE 10, e0134511 (2015). · DOI
  120. Onda, A. et al. Acupuncture ameliorated skeletal muscle atrophy induced by hindlimb suspension in mice. Biochem. Biophys. Res. Commun. 410, 434–439 (2011). · DOI
  121. Liu, Y., Xiao, F. & Liang, X. Acupuncture improves the facial muscular function in a case of facioscapulohumeral muscular dystrophy. J. Acupunct. Meridian Stud. 12, 73–76 (2019). · DOI
  122. Sudhakaran, P. Amyotrophic lateral sclerosis: an acupuncture approach. Med. Acupunct. 29, 260–268 (2017). · DOI
  123. Yu, J., Wang, M., Liu, J., Zhang, X. & Yang, S. Effect of electroacupuncture on the expression of agrin and acetylcholine receptor subtypes in rats with tibialis anterior muscular atrophy induced by sciatic nerve injection injury. Acupunct. Med. 35, 268–275 (2017). · DOI
  124. Su, Z. et al. Acupuncture plus low-frequency electrical stimulation (Acu-LFES) attenuates denervation-induced muscle atrophy. J. Appl. Physiol. 120, 426–436 (2016). · DOI
  125. Che-Yi, C., Wen, C. Y., Min-Tsung, K. & Chiu-Ching, H. Acupuncture in haemodialysis patients at the Quchi (LI11) acupoint for refractory uraemic pruritus. Nephrol. Dial. Transpl. 20, 1912–1915 (2005). · doi:10.1093/ndt/gfh955
  126. Kim, K. H. et al. Acupuncture for symptom management in hemodialysis patients: a prospective, observational pilot study. J. Altern. Complement. Med. 17, 741–748 (2011). · DOI
  127. Su, L. H., Wu, K. D., Lee, L. S., Wang, H. & Liu, C. F. Effects of far infrared acupoint stimulation on autonomic activity and quality of life in hemodialysis patients. Am. J. Chin. Med. 37, 215–226 (2009). · DOI
  128. Munoz-Canoves, P., Scheele, C., Pedersen, B. K. & Serrano, A. L. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J. 280, 4131–4148 (2013). · DOI · Paper page
  129. Kharraz, Y., Guerra, J., Mann, C. J., Serrano, A. L. & Munoz-Canoves, P. Macrophage plasticity and the role of inflammation in skeletal muscle repair. Med. Inflamm. 2013, 491497 (2013). · DOI · Paper page
  130. Mounier, R. et al. AMPKα1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab. 18, 251–264 (2013). · DOI · Paper page
  131. Takaoka, Y. et al. Electroacupuncture suppresses myostatin gene expression: cell proliferative reaction in mouse skeletal muscle. Physiol. Genomics 30, 102–110 (2007). · DOI
  132. Ashby, D. R. et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int. 76, 199–206 (2009). · DOI
  133. Wynne, K. et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J. Am. Soc. Nephrol. 16, 2111–2118 (2005). · DOI · Paper page
  134. Campbell, G. A., Patrie, J. T., Gaylinn, B. D., Thorner, M. O. & Bolton, W. K. Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study. Nephrol. Dial. Transpl. 33, 523–530 (2018). · DOI
  135. Campbell, C. et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve 55, 458–464 (2017). · DOI · Paper page
  136. Perry, B. D. et al. Palmitate-induced ER stress and inhibition of protein synthesis in cultured myotubes does not require Toll-like receptor 4. PLoS ONE 13, e0191313 (2018). · DOI
  137. Woodworth-Hobbs, M. E. et al. Docosahexaenoic acid counteracts palmitate-induced endoplasmic reticulum stress in C2C12 myotubes: impact on muscle atrophy. Physiol. Rep. 5, e13530 (2017). · DOI
  138. Khal, J. & Tisdale, M. J. Downregulation of muscle protein degradation in sepsis by eicosapentaenoic acid (EPA). Biochem. Biophys. Res. Commun. 375, 238–240 (2008). · DOI
  139. Hung, A. M. et al. Omega-3 fatty acids inhibit the up-regulation of endothelial chemokines in maintenance hemodialysis patients. Nephrol. Dial. Transplant. 30, 266–274 (2015). · DOI
  140. Deger, S. M. et al. High dose omega-3 fatty acid administration and skeletal muscle protein turnover in maintenance hemodialysis patients. Clin. J. Am. Soc. Nephrol. 11, 1227–1235 (2016). · DOI
  141. Ishikawa, Y. et al. Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-A(y) mice. Exp. Diabetes Res. 2012, 702948 (2012). · DOI
  142. Hanatani, S. et al. Akt1-mediated fast/glycolytic skeletal muscle growth attenuates renal damage in experimental kidney disease. J. Am. Soc. Nephrol. 25, 2800–2811 (2014). · DOI
  143. Wang, B. et al. Exogenous miR-29a attenuates muscle atrophy and kidney fibrosis in unilateral ureteral obstruction in mice. Hum. Gene Ther. 31, 367–375 (2020). · DOI
  144. Wang, B. et al. miR-26a limits muscle wasting and cardiac fibrosis through exosome-mediated microRNA transfer in chronic kidney disease. Theranostics 9, 1864–1877 (2019). · DOI · Paper page
  145. Zhang, A. et al. Exogenous miR-26a suppresses muscle wasting and renal fibrosis in obstructive kidney disease. FASEB J. 33, 13590–13601 (2019). · DOI
  146. Zhang, A. et al. miRNA-23a/27a attenuates muscle atrophy and renal fibrosis through muscle-kidney crosstalk. J. Cachexia Sarcopenia Muscle 9, 755–770 (2018). · DOI
  147. Wang, H. et al. Exosome-mediated miR-29 transfer reduces muscle atrophy and kidney fibrosis in mice. Mol. Ther. 27, 571–583 (2019). · DOI · Paper page
  148. Rahnert, J. A., Zheng, B., Hudson, M. B., Woodworth-Hobbs, M. E. & Price, S. R. Glucocorticoids alter CRTC-CREB signaling in muscle cells: impact on PGC-1α expression and atrophy markers. PLoS ONE 11, e0159181 (2016). · DOI
  149. Roberts-Wilson, T. K. et al. Calcineurin signaling and PGC-1α expression are suppressed during muscle atrophy due to diabetes. Biochim. Biophys. Acta 1803, 960–967 (2010). · DOI
  150. Peng, H. et al. Myokine mediated muscle-kidney crosstalk suppresses metabolic reprogramming and fibrosis in damaged kidneys. Nat. Commun. 8, 1493 (2017). · DOI · Paper page
  151. Chang, J. S. & Kong, I. D. Irisin prevents dexamethasone-induced atrophy in C2C12 myotubes. Pflug. Arch. 472, 495–502 (2020). · DOI
  152. Chen, J. L. et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 28, 1711–1723 (2014). · DOI · Paper page
  153. Solagna, F. et al. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs. J. Clin. Invest. 131, e135821 (2021). · DOI
  154. Kummer, S., von Gersdorff, G., Kemper, M. J. & Oh, J. The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease. Pediatr. Nephrol. 27, 1213–1219 (2012). · DOI
  155. Jean, G., Souberbielle, J. C. & Chazot, C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients 9, 328 (2017). · DOI · Paper page
  156. Franca Gois, P. H., Wolley, M., Ranganathan, D. & Seguro, A. C. Vitamin D deficiency in chronic kidney disease: recent evidence and controversies. Int. J. Env. Res. Pub. Health 15, 1773 (2018). · DOI
  157. Girgis, C. M. Vitamin D and skeletal muscle: emerging roles in development, anabolism and repair. Calcif. Tissue Int. 106, 47–57 (2020). · DOI
  158. Gordon, P. L., Doyle, J. W. & Johansen, K. L. Association of 1,25-dihydroxyvitamin D levels with physical performance and thigh muscle cross-sectional area in chronic kidney disease stage 3 and 4. J. Ren. Nutr. 22, 423–433 (2012). · DOI
  159. Gordon, P. L., Sakka, G. K., Doyle, J. W., Shubert, T. & Johansen, K. L. Relationship between vitamin D and muscle size and strength in patients on hemodialysis. J. Ren. Nutr. 17, 397–407 (2007). · DOI
  160. Hewitt, N. A., O’Connor, A. A., O’Shaughnessy, D. V. & Elder, G. J. Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 8, 1143–1149 (2013). · DOI
  161. Mager, D. R., Jackson, S. T., Hoffman, M. R., Jindal, K. & Senior, P. A. Vitamin D supplementation, bone health and quality of life in adults with diabetes and chronic kideney disease: results of an open label randomized clinical trial. Clin. Nutr. 36, 686–696 (2017). · DOI
  162. Morvan, F. et al. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proc. Natl Acad. Sci. USA 114, 12448–12453 (2017). · DOI · Paper page
  163. Chen, J. L. et al. Development of novel activin-targeted therapeutics. Mol. Ther. 23, 434–444 (2015). · DOI
  164. Zhang, L. et al. Stat3 activation links a C/EBPdelta to myostatin pathway to stimulate loss of muscle mass. Cell Metab. 18, 368–379 (2013). · DOI · Paper page

Cited by

See all 170

Metadata

Authors
Wang, X. H., Mitch, W. E., & Price, S. R.
Venue
Nature Reviews Nephrology
Published
2021-11-08
Volume
18
Issue
3
Pages
138-152
ISSN
  • 1745-8323 (ISSN-L)
  • 1759-5061
  • 1759-507X
OpenAlex
W3214295340
Cited by
170
References
31
FWCI
2.17
Type
journal article
Language
en
Open access
closed
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathophysiological mechanisms leading to muscle loss in chronic kidney disease. https://app.cochat.ai/papers/10.1038/s41581-021-00498-0
The paper
Wang, X. H., Mitch, W. E., & Price, S. R. (2022). Pathophysiological mechanisms leading to muscle loss in chronic kidney disease. Nature Reviews Nephrology. https://doi.org/10.1038/s41581-021-00498-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.